TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar) for recurrent nasopharyngeal carcinoma

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016085

Enrollment

Unknown

Registered

2018-05-09

Start date

2013-01-01

Completion date

Unknown

Last updated

2018-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal Carcinoma

Interventions

Case series:TP-induction chemotherapy plus Intensity Modulated Radiaotherapy combined with anti-angiogenic targeted drugs (endostar)

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) pathologically confirmed local recurrent nasopharyngeal carcinoma; (2) Aged 18 to 60 years old; (3) KPS=70; (4) normal blood routine, heart, liver and kidney function; (5) no treatment was performed after recurrence of the diagnosis; (6) no allergic reaction to biological agents; (7) Able to understand the situation of this study and have signed informed consent.

Exclusion criteria

Exclusion criteria: (1) distant metastasis; (2) recurrence of regional lymph nodes; (3) pregnancy or lactation; (4) severe coronary heart disease or hypertension; (5) liver and renal insufficiency.

Design outcomes

Primary

Measure	Time frame
Acute toxicity;short term effect;	—

Countries

China

Contacts

Public ContactZhao Chong

Sun Yat-sen University Cancer Center

gzzhaochong@163.com+86 020-87343384

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026